Table 3.
Univariate and multivariate analysis of risk factors for SARS-CoV-2-related mortality in the remdesivir cohort.
| Variables | Log. Regr. COVID-19 Mortality * (n = 21 Out of 243) |
|||
|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||
| OR (95% C.I.) % (95%C.I.) |
P | OR (95% C.I.) | P | |
| Age (years), | ||||
| • <41 years | 1 | |||
| • 41–60 years | 0.6 (0.06–6.2) | 0.68 | ||
| • 61–70 years | 1.5 (0.15–14.5) | 0.7 | ||
| • >71 years | 2.87 (0.35–23) | 0.3 | ||
| Male, n (%) | 0.41 (0.17–1.06) | 0.069 | 0.35 (0.13–0.96) | 0.042 |
| Baseline disease, n (%) | ns | |||
| • AML | 1 | |||
| • ALL | - | |||
| • MDS | 1.02 (0.12–3.5) | 0.8 | ||
| • CMPD | 1.7 (0.14–21) | 0.65 | ||
| • B-cell NHL | 3.9 (0.83–18) | 0.08 | ||
| • T-cell NHL | 3.2 (0.25–41) | 0.36 | ||
| • CLL | 3.44 (0.52–22) | 0.19 | ||
| • Plasmatic cell disorder | 0.52 (0.04–6.06) | 0.6 | ||
| • HD | - | |||
| • AA or others | - | |||
| Time from last therapy to COVID-19 | ||||
| • <6 months | 1 | |||
| • 6–12 months | 2.08 (0.54–7.9) | 0.28 | ||
| • >12 months or not treated | 0.85 (0.23–3.1) | 0.8 | ||
| Prior anti-CD20 therapy | 3.44 (1.38–8.5) | 0.008 | ns | |
| Time from anti-CD 20 to COVID-19, n (%) | ns | |||
| • No anti-CD20 | 1 | |||
| • <6 months | 2.47 (0.87–6.9) | 0.08 | ||
| • 6–12 months | 17.6 (3.12–100) | 0.001 | ||
| • >12 months or not treated | 3.5 (0.6–18.5) | 0.13 | ||
| Corticosteroids at the time of COVID-19 | 1.03 (0.38–2.7) | 0.9 | ||
| Procedure | ||||
| • Non-SCT | 0.88 (.27–3.2) | 0.8 | ||
| • Allo-SCT | 1 | |||
| • ASCT | 1.2 (0.06–5.6) | 0.8 | ||
| • CAR-T | 1.83 (0.25–13) | 0.54 | ||
| Vaccination status© | ||||
| • Complete | 1 | |||
| • Incomplete | 1.1 (0.45–2.85) | 0.78 | ||
| Pulmonary/cardiovascular risk factors, n (%) | ||||
| • Active smoking | 0.5 (0.06–3.9) | 0.5 | ||
| • Arterial hypertension | 2.8 (1.1–7.2) | 0.032 | ns | |
| • Cardiomyopathy | 3.3 (1.3–8.5) | 0.011 | ns | |
| • Pulmonary disease | 2.8 (1.01–7.8) | 0.05 | ns | |
| Other COVID-19 therapies | ||||
| • Convalescent plasma | 0.33 (0.04–2.5) | 0.29 | ||
| • Monoclonal antibodies | 0.99 (0.31–3.1) | 0.9 | ||
| • Corticosteroids | 11 (3.55–33.8) | <0.0001 | 9.4 (2.9–30.2) | <0.001 |
| Co-infection | 4.59 (1.8–11.6) | 0.001 | 2.8 (1.01–7.7) | 0.047 |
| ATV onset | ||||
| • <5 days | 1 | |||
| • ≥5 days | 1.48 (0.54–4.04) | 0.43 | ||
| Duration of remdesivir | ||||
| • <5 days | 1.13 (0.4–3.1) | 0.8 | ||
| • 5 days | 1 | |||
| • >5 days | 1.17 (0.36–3.78) | 0.78 | ||
| Ct value at diagnosis * | ||||
| • ≥20 | 1 | |||
| • <20 | 1.35 (0.41–4.3) | 0.61 | ||
| CRP > 8 UI/mL * | 1.8 (0.5–5.2) | 0.9 | ||
| ALC < 0.5 × 109/L * | 0.74 (0.13–3.9) | 0.7 | ||
| ANC < 0.5 × 109/L * | 1.1 (0.13–10.2) | 0.9 | ||
Abbreviations: SCT, stem cell transplantation; ASCT, autologous hematopoietic stem cell transplantation; allo-SCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; cMPD, chronic myeloproliferative disease; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; AA, aplastic anemia; Ct, PCR cycle threshold; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; CRP, C-reactive protein; ns, not significant. * These variables have not been tested since there is a lack of data in more than 40% of cases. © Complete vaccination was defined as at least 3 vaccine doses, whereas incomplete includes 2 or less.